Targeting the CD44-SPP1 Axis: A New Frontier in Bladder Cancer ResistanceByHiba Siddiqui, BScMay 8th 2026Characterizing the heterogeneity of the CD44-SPP1 axis could help to identify therapeutic strategies for patients with advanced bladder cancer.